Development of GATE Monte Carlo Code for Simulation and Dosimetry of New I-125 Seeds in Eye Plaque Brachytherapy
10.1007/s13139-020-00680-5
- Author:
Payvand TAHERPARVAR
1
;
Zeinab FARDI
Author Information
1. Department of Physics, Faculty of Science, University of Guilan, Namjoo Avenue, P.O. Box 41635-1914, Rasht, Guilan 4193833697, Iran
- Publication Type:ORIGINAL ARTICLE
- From:Nuclear Medicine and Molecular Imaging
2021;55(2):86-95
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Dose distributions are calculated by Monte Carlo (MC) simulations for two low-energy models 125 I brachytherapy source—IrSeed-125 and IsoAid Advantage (model IAI-125A)—loaded in the 14-mm standardized plaque of the COMS during treatment of choroid melanoma.
Methods:In this study, at first, the radial dose function in water around 125 I brachytherapy sources was calculated based on the recommendations of the Task Group No. 43 American Association of Physicists in Medicine (TG-43U1 APPM) using by GATE code. Then, brachytherapy dose distribution of a new model of the human eye was investigated for a 14-mm COMS eye plaque loaded with these sources with GATE Monte Carlo simulation.
Results:Results show that there are good agreements between simulation results of these sources and reporting measurements and simulations. Dosimetry results in the designed eye phantom for two types of iodine seeds show that the ratios of average dose of tumor to sclera, vitreous, and retina for IrSeed (IsoAid) source are 3.7 (3.7), 6.2 (6.1), and 6.3 (6.3), respectively, which represents the dose saving to healthy tissues. The maximum percentage differences between DVH curve of IsoAid and IrSeed seeds was about 8%.
Conclusions:Our simulation results show that although new model of the 125 I brachytherapy source having a slightly larger dimension than IAI-125A, it can be used for eye melanoma treatment because the COMS eye plaque loaded with IrSeed-125 could produce similar results to the IsoAid seeds, which is applicable for clinical plaque brachytherapy for uveal melanoma.
